Literature DB >> 28659438

Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice.

Judith R Reinhard1, Shuo Lin1, Karen K McKee2, Sarina Meinen1, Stephanie C Crosson2, Maurizio Sury1, Samantha Hobbs2, Geraldine Maier1, Peter D Yurchenco2, Markus A Rüegg3.   

Abstract

LAMA2-related muscular dystrophy (LAMA2 MD or MDC1A) is the most frequent form of early-onset, fatal congenital muscular dystrophies. It is caused by mutations in LAMA2, the gene encoding laminin-α2, the long arm of the heterotrimeric (α2, β1, and γ1) basement membrane protein laminin-211 (Lm-211). We establish that despite compensatory expression of laminin-α4, giving rise to Lm-411 (α4, β1, and γ1), muscle basement membrane is labile in LAMA2 MD biopsies. Consistent with this deficit, recombinant Lm-411 polymerized and bound to cultured myotubes only weakly. Polymerization and cell binding of Lm-411 were enhanced by addition of two specifically designed linker proteins. One, called αLNNd, consists of the N-terminal part of laminin-α1 and the laminin-binding site of nidogen-1. The second, called mini-agrin (mag), contains binding sites for laminins and α-dystroglycan. Transgenic expression of mag and αLNNd in a mouse model for LAMA2 MD fully restored basement membrane stability, recovered muscle force and size, increased overall body weight, and extended life span more than five times to a maximum survival beyond 2 years. These findings provide a mechanistic understanding of LAMA2 MD and establish a strong basis for a potential treatment.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28659438      PMCID: PMC5744687          DOI: 10.1126/scitranslmed.aal4649

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  66 in total

1.  Survival characteristics and age-adjusted disease incidences in C57BL/6 mice fed a commonly used cereal-based diet modulated by dietary restriction.

Authors:  Angelo Turturro; Peter Duffy; Bruce Hass; Ralph Kodell; Ronald Hart
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-11       Impact factor: 6.053

2.  Contractile properties of skeletal muscles from young, adult and aged mice.

Authors:  S V Brooks; J A Faulkner
Journal:  J Physiol       Date:  1988-10       Impact factor: 5.182

3.  Transgenic overexpression of laminin alpha1 chain in laminin alpha2 chain-deficient mice rescues the disease throughout the lifespan.

Authors:  Kinga I Gawlik; Madeleine Durbeej
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

4.  Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.

Authors:  Jinger A Doe; Ryan D Wuebbles; Erika T Allred; Jachinta E Rooney; Margaret Elorza; Dean J Burkin
Journal:  J Cell Sci       Date:  2011-06-07       Impact factor: 5.285

5.  An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy.

Authors:  J Moll; P Barzaghi; S Lin; G Bezakova; H Lochmüller; E Engvall; U Müller; M A Ruegg
Journal:  Nature       Date:  2001-09-20       Impact factor: 49.962

6.  Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies.

Authors:  Daniel E Michele; Rita Barresi; Motoi Kanagawa; Fumiaki Saito; Ronald D Cohn; Jakob S Satz; James Dollar; Ichizo Nishino; Richard I Kelley; Hannu Somer; Volker Straub; Katherine D Mathews; Steven A Moore; Kevin P Campbell
Journal:  Nature       Date:  2002-07-25       Impact factor: 49.962

7.  Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse.

Authors:  Alexandre Briguet; Isabelle Courdier-Fruh; Mark Foster; Thomas Meier; Josef P Magyar
Journal:  Neuromuscul Disord       Date:  2004-10       Impact factor: 4.296

8.  Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.

Authors:  Jenny Yamauchi; Ajay Kumar; Lina Duarte; Thomas Mehuron; Mahasweta Girgenrath
Journal:  Hum Mol Genet       Date:  2013-06-16       Impact factor: 6.150

9.  Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice.

Authors:  Sarina Meinen; Shuo Lin; Raphael Thurnherr; Michael Erb; Thomas Meier; Markus A Rüegg
Journal:  EMBO Mol Med       Date:  2011-06-15       Impact factor: 12.137

10.  Matrix assembly, regulation, and survival functions of laminin and its receptors in embryonic stem cell differentiation.

Authors:  Shaohua Li; David Harrison; Salvatore Carbonetto; Reinhard Fassler; Neil Smyth; David Edgar; Peter D Yurchenco
Journal:  J Cell Biol       Date:  2002-06-24       Impact factor: 10.539

View more
  23 in total

1.  Efficient myotube formation in 3D bioprinted tissue construct by biochemical and topographical cues.

Authors:  WonJin Kim; Hyeongjin Lee; JiUn Lee; Anthony Atala; James J Yoo; Sang Jin Lee; Geun Hyung Kim
Journal:  Biomaterials       Date:  2019-11-19       Impact factor: 12.479

2.  Soluble Heparin Binding Epidermal Growth Factor-Like Growth Factor Is a Regulator of GALGT2 Expression and GALGT2-Dependent Muscle and Neuromuscular Phenotypes.

Authors:  Megan L Cramer; Rui Xu; Paul T Martin
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

Review 3.  Alport syndrome and Pierson syndrome: Diseases of the glomerular basement membrane.

Authors:  Steven D Funk; Meei-Hua Lin; Jeffrey H Miner
Journal:  Matrix Biol       Date:  2018-04-16       Impact factor: 11.583

4.  Pathogenicity of a Human Laminin β2 Mutation Revealed in Models of Alport Syndrome.

Authors:  Steven D Funk; Raymond H Bayer; Andrew F Malone; Karen K McKee; Peter D Yurchenco; Jeffrey H Miner
Journal:  J Am Soc Nephrol       Date:  2017-12-20       Impact factor: 10.121

Review 5.  Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies.

Authors:  Peter D Yurchenco; Karen K McKee; Judith R Reinhard; Markus A Rüegg
Journal:  Matrix Biol       Date:  2017-11-27       Impact factor: 11.583

6.  PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Feng Yue; Changyou Song; Di Huang; Naagarajan Narayanan; Jiamin Qiu; Zhihao Jia; Zhengrong Yuan; Stephanie N Oprescu; Bruno T Roseguini; Meng Deng; Shihuan Kuang
Journal:  Mol Ther       Date:  2020-09-23       Impact factor: 11.454

Review 7.  Muscle Wasting Diseases: Novel Targets and Treatments.

Authors:  Regula Furrer; Christoph Handschin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-08-27       Impact factor: 13.820

Review 8.  At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?

Authors:  Kinga I Gawlik
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

9.  Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin.

Authors:  Chunping Qiao; Yi Dai; Viktoriya D Nikolova; Quan Jin; Jianbin Li; Bin Xiao; Juan Li; Sheryl S Moy; Xiao Xiao
Journal:  Mol Ther Methods Clin Dev       Date:  2018-01-31       Impact factor: 6.698

10.  Brain Dysfunction in LAMA2-Related Congenital Muscular Dystrophy: Lessons From Human Case Reports and Mouse Models.

Authors:  Andrea J Arreguin; Holly Colognato
Journal:  Front Mol Neurosci       Date:  2020-07-23       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.